Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

about

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

Item

http://www.wikidata.org/entity/Q48298916

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

@en

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

@nl

type

Item

label

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

@en

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

@nl

prefLabel

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

@en

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

@nl

P1476

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA

@en

P2093

Jing Li

http://www.w3.org/2001/XMLSchema#string

Yan Wang

http://www.w3.org/2001/XMLSchema#string

Ying Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists

Molecular mechanisms of epithelial-mesenchymal transition

Immunological properties of engineered nanomaterials

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.

Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor

HPMA copolymers: origins, early developments, present, and future.

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

P304

1395-1404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACS.MOLPHARMACEUT.6B00999

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Oupický

Zheng-Hong Peng

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28134535

http://www.w3.org/2001/XMLSchema#string

P932

5417087

http://www.w3.org/2001/XMLSchema#string